Brief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study

Pharnext SCA

28/02/2024 07:48

Feb 28 (Reuters) - Pharnext SCA  PHARN.PA :
    * PHARNEXT PROGRESSES IN ANALYZING DATA FROM PIVOTAL PHASE
III
STUDY OF PXT3003 IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
    * ENCOURAGING RESULTS, SEVERAL ADDITIONAL STUDIES ENABLED TO
REFINE OUR CONCLUSIONS AT THIS STAGE, WITH ANALYSIS CONTINUING
AND EXTENDING THROUGH Q1 2024
    * WE ARE CONTINUING OUR OWN ANALYSES AND WILL NEED TO
DISCUSS WITH
FDA AND EMA TO AGREE ON A REGISTRATION PATHWAY
    * IF RESULTS OF PHASE III TRIAL IN CHINA ARE POSITIVE, AND
EVEN
WITHOUT FDA OR EMA APPROVAL, COMPANY WILL THEN BE ABLE TO
FINANCE ITSELF OVER COMING YEARS SOLELY THROUGH REVENUES FROM
CHINESE LICENSE

Source text for Eikon:  urn:newsml:reuters.com:*:nACT84372
Further company coverage:  PHARN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))